Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Enochian Biosciences, Inc. (ENOB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4500-0.1100 (-4.30%)
At close: 04:00PM EDT
2.4200 -0.03 (-1.22%)
After hours: 06:20PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5600
Open2.6000
Bid2.4200 x 900
Ask2.7600 x 1100
Day's Range2.4000 - 2.5200
52 Week Range1.4200 - 13.7800
Volume38,457
Avg. Volume476,970
Market Cap127.938M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.6650
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

    LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley

  • The Wall Street Journal

    Enochian Biosciences Finds Falsified Data in Study of Covid-19 Treatment

    The allegations are the latest against biotech wizard Serhat Gumrukcu who was indicted in a murder-for-hire case in recent months.

  • GlobeNewswire

    Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data

    LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Company’s pipelines. The results of this investigation verified key primary data for the Company’s HIV and cancer pipelines. The investigation also verified the primary data from an animal model with intravenous delivery of a potential treatment for COVID-19 that was

Advertisement
Advertisement